IP Verse

Methods Of Treatment Of Ocular Conditions With A Sustained Drug Delivery Implant

Patent No. EP3068403 (titled "Methods Of Treatment Of Ocular Conditions With A Sustained Drug Delivery Implant") was filed by Allergan on Nov 14, 2014. The application was issued on Dec 3, 2025.

Patent Summary

Bioerodible implant for treating diabetic macular edema (DME) by injecting it into the vitreous of the eye at intervals of 6 months to 9 months. The implant contains dexamethasone dispersed in a biodegradable polymer matrix. The polymer is a mixture of PLGA with hydrophilic and hydrophobic end groups. The implant size is chosen for vitreous injection. The implant is administered repeatedly over multiple years to treat DME.

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
DF MP DRRIES FRANK MOLNIA & POHLMANMar 16, 2021GREINER
DF MP DORRIES FRANK MOLNIA & POHLMAN PATENTANWALTE RECHTSANWALTE PARG MBBMar 16, 2021GREINER

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3068403

ALLERGAN
Application Number
EP14805768A
Filing Date
Nov 14, 2014
Status
Patent Maintained As Amended
Oct 31, 2025
Publication Date
Dec 3, 2025
External Links
Slate, Register , Google Patents